Associated equity: IRLAB Therapeutics
Edison Investment Research has terminated coverage on IRLAB Therapeutics (IRLAB-A). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
IRLAB Therapeutics — 7 videos in collection
IRLAB Therapeutics AB is dedicated to the discovery and development of new drugs for treatment of Parkinson’s disease and other life-altering diseases that affect the central nervous system (CNS). IRLAB strive to transform the everyday life for patients who lack effective treatment options.
• Tell us about the company, its key assets and the particular areas of focus.
• What is IRLAB’s proprietary ISP platform, which leads to these discoveries?
• Tell us about some of the company’s assets.
• Tell us more about the successful deal to out-license your lead asset Mesdopetam to Ipsen in summer 2021.
• At what stage is pirepemat, your next most advanced Parkinson’s asset, in its development timeline?
• Are the other developments in your pipeline also assets focusing on the neglected effects of Parkinson’s disease?
• Which milestones should investors look out for in the coming year?